RedHill Biopharma’s RHB-104 shows promise in Phase III study

About 1.5 million people across the globe have Crohn’s disease which is a difficult disease to treat. But now Redhill Biopharma have reported the double-blind, placebo-controlled Phase III trials of their Crohn’s disease drug RHB-104 have shown promise.
Ira Kalfus, RedHill’s medical director, said: “The availability of antibiotic therapy for treating Crohn’s disease could be transformative. The results from the MAP US study are excellent, successfully meeting the primary endpoint at week 26 and demonstrating that treatment with RHB-104 also has an early benefit at week 16, which is persistent though week 52. The study results compare favourably to existing standard-of-care therapies.”
Lead investigator of the study, Professor David Graham, said: “I am impressed and extremely pleased with the results of the study, which indicate that RHB-104 could lead to a paradigm shift in the treatment of Crohn’s disease, a chronic and debilitating and currently incurable condition with a strong unmet medical need. Many patients with Crohn’s disease do not achieve remission on current standard-of-care therapies, which are accompanied with poor side effects. RHB-104 appears to have the potential to become a promising, new, orally-administered therapy for this important debilitating disease.”